Attovia Therapeutics, Inc. (ATTO) |
| 20.7 -0.76 (-3.54%) 08-28 16:00 |
| Open: | 21.37 |
| High: | 21.54 |
| Low: | 20.22 |
| Volume: | 127,603 |
| Market Cap: | 891(M) |
| PE Ratio: | 0 |
| Exchange: | NASDAQ |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 28.41 |
| Resistance 1: | 24.32 |
| Pivot price: | 20.42 |
| Support 1: | 19.27 |
| Support 2: | 16.15 |
| 52w High: | 24.32 |
| 52w Low: | 16.15 |
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Financials
| EPS | -70110000.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -5.00 |
| Return on Assets (ttm) | 260.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Fri, 28 Aug 2026
Goldman to sell $2.2M in Attovia Therapeutics (ATTO) stock - Stock Titan
Fri, 28 Aug 2026
Goldman units trade Attovia Therapeutics (ATTO) shares, add swaps - Stock Titan
Fri, 28 Aug 2026
Goldman units log Attovia (NASDAQ: ATTO) 500K-share buy and equity swap trades - Stock Titan
Wed, 19 Aug 2026
Number of shareholders of Attovia Therapeutics, Inc. – NASDAQ:ATTO - TradingView
Thu, 06 Aug 2026
Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - Yahoo Finance
Wed, 05 Aug 2026
Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO - Fierce Biotech
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
